Adaptive Biotechnologies

$67.74
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.73 (+1.09%) Today

$0.00 (0.00%) As of 9:14 AM UTC after-hours

Why Robinhood?

You can buy or sell ADPT and other stocks, options, and ETFs commission-free!

About ADPT

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA. The listed name for ADPT is Adaptive Biotechnologies Corporation Common Stock.

CEO

Chad Robins

Employees

453

Headquarters

Seattle, Washington

Founded

2009

Market Cap

9.24B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

920.68K

High Today

$68.13

Low Today

$65.81

Open Price

$66.71

Volume

293.17K

52 Week High

$71.25

52 Week Low

$15.19

Collections

Analyst Ratings

88%

of 8 ratings

Buy

88%

Hold

13%

Sell

ADPT Earnings

-$1.23

-$0.82

-$0.41

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 24, After Hours